N¹-(4-(methylthio)phenyl)benzene-1,2-diamine | 208922-40-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N¹-(4-(methylthio)phenyl)benzene-1,2-diamine
• 英文别名: N-4-methylthiophenyl-o-phenylenediamine；2-N-(4-methylsulfanylphenyl)benzene-1,2-diamine
• CAS: 208922-40-1
• 化学式: C₁₃H₁₄N₂S
• mdl: MFCD11201698
• 分子量: 230.334
• InChiKey: FPYBNGGOOLNDQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  63.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N¹-(4-(methylthio)phenyl)benzene-1,2-diamine 在 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 3-N-[2-(4-methylsulfanylanilino)phenyl]-4,6-dinitro-1-N-pyridin-3-ylbenzene-1,3-diamine
  参考文献：
  名称：

  Identification of Less Lipophilic Riminophenazine Derivatives for the Treatment of Drug-Resistant Tuberculosis

  摘要：

  Clofazimine (CFZ), a member of the riminophenazine class, has been studied in clinical trials for the treatment of multidrug-resistant tuberculosis (MDR-TB). CFZ has several side effects which can be attributed to its extremely high lipophilicity. A series of novel riminophenazine analogues bearing a C-2 pyridyl substituent was designed and synthesized with the goal of maintaining potent activity against Mycobacterium tuberculosis (M. tuberculosis) while improving upon its safety profile by lowering the lipophilicity. All compounds were evaluated for their in vitro activity and cytotoxicity. The results demonstrated that many new compounds had potent activity against M. tuberculosis with MICs of less than 0.03 mu g/mL and low cytotoxicity with IC50 values greater than 64 mu g/mL. Some compounds were tested for in vivo efficacy against MDR-TB in an experimental mouse infection model. Two compounds demonstrated equivalent or better efficacy than CFZ in this model with significantly reduced skin discoloration potential.

  DOI：

  10.1021/jm300828h
• 作为产物：
  描述：

  1-氟-2-硝基苯 在 铁粉 、 溶剂黄146 作用下， 反应 1.0h， 生成 N¹-(4-(methylthio)phenyl)benzene-1,2-diamine
  参考文献：
  名称：

  仿生四氧嘧啶催化的分子内氧化还原反应与O 2：一锅原子经济合成亚磺酰基官能化苯并咪唑

  摘要：

  鉴于在各种仿生需氧氧化中必须使用牺牲性还原剂，通过巧妙地结合底物硫化物和牺牲性还原剂，开发了用于一锅原子经济合成亚磺酰基官能化苯并咪唑的四氧嘧啶催化的有氧氧化还原系统。除了对环境无害的分子氧以外，这种温和且无过渡金属的方案无需额外的牺牲试剂即可进行两次氧化。

  DOI：

  10.1016/j.tetlet.2020.152688

文献信息

• Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists
  作者：Pradip K. Sasmal、Sanjita Sasmal、P. Tirumala Rao、B. Venkatesham、M. Roshaiah、Chandrasekhar Abbineni、Ish Khanna、Vikram P. Jadhav、J. Suresh、Rashmi Talwar、Syed Muzeeb、Jean-Marie Receveur、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2010.07.086

  日期：2010.9

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.
• Benzimidazole compounds
  申请人：PFIZER INC.

  公开号：EP0846689B1

  公开（公告）日：2004-01-14
• Biomimetic alloxan-catalyzed intramolecular redox reaction with O2: One-pot atom-economic synthesis of sulfinyl-functionalized benzimidazoles
  作者：Shiqi Zhang、Dong Yi、Guangxun Li、Ling Li、Gang Zhao、Zhuo Tang

  DOI：10.1016/j.tetlet.2020.152688

  日期：2021.1

  Given the necessity of sacrificial reductants in various biomimetic aerobic oxygenations, alloxan-catalyzed aerobic redox system for one-pot atom-economic synthesis of sulfinyl-functionalized benzimidazoles was developed by ingeniously binding both the substrate sulfide and sacrificial reductant. This mild and transition-metal-free protocol undergoes two oxidations without additional sacrificial reagents

  鉴于在各种仿生需氧氧化中必须使用牺牲性还原剂，通过巧妙地结合底物硫化物和牺牲性还原剂，开发了用于一锅原子经济合成亚磺酰基官能化苯并咪唑的四氧嘧啶催化的有氧氧化还原系统。除了对环境无害的分子氧以外，这种温和且无过渡金属的方案无需额外的牺牲试剂即可进行两次氧化。
• Identification of Less Lipophilic Riminophenazine Derivatives for the Treatment of Drug-Resistant Tuberculosis
  作者：Dongfeng Zhang、Yu Lu、Kai Liu、Binna Liu、Jingbin Wang、Gang Zhang、Hao Zhang、Yang Liu、Bin Wang、Meiqin Zheng、Lei Fu、Yanyan Hou、Ningbo Gong、Yang Lv、Chun Li、Christopher B. Cooper、Anna M. Upton、Dali Yin、Zhenkun Ma、Haihong Huang

  DOI：10.1021/jm300828h

  日期：2012.10.11

  Clofazimine (CFZ), a member of the riminophenazine class, has been studied in clinical trials for the treatment of multidrug-resistant tuberculosis (MDR-TB). CFZ has several side effects which can be attributed to its extremely high lipophilicity. A series of novel riminophenazine analogues bearing a C-2 pyridyl substituent was designed and synthesized with the goal of maintaining potent activity against Mycobacterium tuberculosis (M. tuberculosis) while improving upon its safety profile by lowering the lipophilicity. All compounds were evaluated for their in vitro activity and cytotoxicity. The results demonstrated that many new compounds had potent activity against M. tuberculosis with MICs of less than 0.03 mu g/mL and low cytotoxicity with IC50 values greater than 64 mu g/mL. Some compounds were tested for in vivo efficacy against MDR-TB in an experimental mouse infection model. Two compounds demonstrated equivalent or better efficacy than CFZ in this model with significantly reduced skin discoloration potential.